bufexamac   Click here for help

GtoPdb Ligand ID: 7498

Synonyms: CP-1044-J3 | Paraderm® | Parfenac®
Approved drug PDB Ligand
bufexamac is an approved drug
Compound class: Synthetic organic
Comment: In addition to inhibition of COX enzymes, this drug has been discovered to inhibit class IIb HDACs (ie HDACs 6 and 10) [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 1
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 58.56
Molecular weight 223.12
XLogP 2.07
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CCCCOc1ccc(cc1)CC(=O)NO
Isomeric SMILES CCCCOc1ccc(cc1)CC(=O)NO
InChI InChI=1S/C12H17NO3/c1-2-3-8-16-11-6-4-10(5-7-11)9-12(14)13-15/h4-7,15H,2-3,8-9H2,1H3,(H,13,14)
No information available.
Summary of Clinical Use Click here for help
Bufexamac is a non-steroidal anti-inflammatory drug (NSAID). This drug was used to control the symptoms of inflammation of the skin (such as redness and itching) in diseases such as eczema and dermatitis. However, the EMA revoked marketing authorisation for medicines containing bufexamac throughout the European Union in 2010 due to an unacceptable risk of developing contact dermatitis. Other countries may still approve use of this drug.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
This drug was originally believed to primarily be a cyclooxygenase (COX) inhibitor, although its precise MMOA remains unclear [2]. More recently, bufexamac has been discovered to inhibit HDACs 6 and 10, and subsequently inhibit IFN-α secretion [1], which may contribute to its anti-inflammatory action.